Home » Orexigen Begins Obesity Trial
Orexigen Begins Obesity Trial
Orexigen Therapeutics has started the fourth trial in its Phase III clinical trial program for Contrave as a treatment for obesity.
The 56-week trial will assess the safety, tolerability and efficacy of Contrave in healthy, nondiabetic, obese patients. At week 28, nonresponding patients will be rerandomized to receive either a higher dose of Contrave or continue on their original doses.
Gary Tollefson, Orexigen’s president and CEO, said the company intends to submit a new drug application for Contrave in the second half of 2009.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May